Active substance:
Moxifloxacin
Pharmacotherapeutic group:
Antiinfectives for systemic use, Antibacterials for systemic use, Quinolone antibacterials, Fluoroquinolones
ATC code: J01MA14
Mechanism of action:
The mechanism of action of moxifloxacin is based on disruption of DNA synthesis by inhibition of bacterial topoisomerase II (gyrase) and topoisomerase IV.
Therapeutic indications:
Moxifloxacin Eberth is indicated in adults for the treatment of:
- Community acquired pneumonia (CAP)
- Complicated skin and skin structure infections (cSSSI)
Moxifloxacin Eberth should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.